CardioVascular and Interventional Radiology · 2021 · 30 citations · 49 references
MedicineOncologySurgeryCancer ControlOncologic SurgerySurgical OncologyInterventional OncologyTherapy Response AssessmentComplete Response AssessmentControl Group DesignHepatocellular Carcinoma TreatmentMatched Control GroupMicrospheresPost-treatment Response AssessmentPropensity Score AdjustmentTumor Embolization
PURPOSE: The aim of this retrospective multicentric study was to compare the tumour response rates of Balloon-occluded Transarterial Chemoembolisation (B-TACE) to non-B-TACE using propensity score matching (PSM) in patients with hepatocellular carcinoma and to investigate the clinical benefit, such as lower rates of TACE re-intervention achieved using B-TACE. MATERIAL AND METHODS: The B-TACE procedures (n = 96 patients) were compared with a control group of non-B-TACE treatments (n = 434 pts), performed with conventional (cTACE) or drug-eluting microspheres TACE (DEM-TACE). Data were collected from six European centres from 2015 to 2019. Objective responses (OR) and complete response (CR) rates after the first session and the number of TACE re-interventions were evaluated using PSM (91 patients per arm). RESULTS: The best target OR after PSM were similar for both B-TACE and non-B-TACE (90.1% and 86.8%, p = 0.644); however, CR at 1-6 months was significantly higher for B-TACE (59.3% vs. 41.8%, p = 0.026). Patients treated with B-TACE had a significantly lower retreatment rate during the first 6 months (9.9%% vs. 22.0%, p = 0.041). Post-embolisation syndrome (PES) rates were 8.8% in non-B-TACE and 41.8% in B-TACE (p < 0.001), with no significant differences between groups regarding major adverse events. CONCLUSION: B-TACE is safe and effective, achieving higher CR rates than non-B-TACE. Patients undergoing B-TACE had a significantly lower retreatment rate within the first 6 months but higher PES rates. LEVEL OF EVIDENCE III: Level 3, retrospective study.
49
Management of Hepatocellular Carcinoma *
Jordi Bruix, Morris Sherman · Hepatology · 2005 · 5.9K citations · Full text
Josep M. Llovet, Andrew K. Burroughs, Jordi Bruix · The Lancet · 2003 · 3.6K citations
Annals of Internal Medicine · 1977 · 2.1K citations
Medicine, Oncology, Pharmacology +17
Johannes Lämmer, Katarina Malagari, Thomas J. Vogl et al. · CardioVascular and Interventional Radiology · 2009 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +15